Overview

A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Relapsing Forms of Multiple Sclerosis

Status:
Completed
Trial end date:
2021-09-09
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of elezanumab in participants with relapsing Multiple Sclerosis (RMS).
Phase:
Phase 2
Details
Lead Sponsor:
AbbVie